Ironwood raises FY2026 guidance after strong Q2; LINZESS sales up 44% YTD

IRONWOOD PHARMACEUTICALS INC

Q2 total revenue $113M, GAAP net income $51M ($0.31 diluted EPS), adjusted EBITDA $83M.
LINZESS U.S. net sales Q2 $282M, YTD $555M (+44% YoY).
FY2026 guidance raised: LINZESS net sales $1.15-1.20B, total revenue $460-485M, adjusted EBITDA >$310M.
Repaid $200M convertible notes with cash on hand; balance sheet strengthening.
Confirmatory Phase 3 STARS-2 trial of apraglutide in SBS-IF actively recruiting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.